Novolog

GPTKB entity

Statements (59)
Predicate Object
gptkbp:instance_of gptkb:Company
gptkbp:bfsLayer 3
gptkbp:bfsParent gptkb:Company
gptkbp:brand gptkb:Novo_Log
gptkbp:clinical_trial insulin pump therapy
studied for efficacy
studied for safety
mealtime insulin
gptkbp:contraindication severe hypoglycemia
hypersensitivity to insulin aspart
gptkbp:dosage_form solution for injection
gptkbp:duration 3 to 5 hours
gptkbp:education insulin administration techniques
diet and exercise recommendations
hypoglycemia management
gptkbp:effective_date gptkb:2000
gptkbp:form vials
pre-filled pens
gptkbp:formulation injectable solution
gptkbp:highest_point 1 to 3 hours
https://www.w3.org/2000/01/rdf-schema#label Novolog
gptkbp:ingredients gptkb:insulin_aspart
gptkbp:interacts_with gptkb:beer
beta-blockers
thiazide diuretics
gptkbp:invention patented
generic versions available
gptkbp:is_monitored_by blood glucose levels
Hb A1c levels
gptkbp:is_used_for diabetes management
gptkbp:manager subcutaneous injection
gptkbp:manufacturer gptkb:Novo_Nordisk
gptkbp:marketed_as gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
gptkbp:packaging multi-dose vials
single-dose pens
gptkbp:pharmacokinetics rapid-acting insulin
absorbed quickly
peak effect within 1-3 hours
gptkbp:population Type 1 diabetes patients
Type 2 diabetes patients
gptkbp:premiered_on 10 to 20 minutes
gptkbp:price varies by region
insurance coverage may apply
gptkbp:products gptkb:Fiasp
gptkb:Novo_Log_Mix_70/30
gptkbp:provides_information_on EASD guidelines
ADA guidelines
gptkbp:regulatory_compliance FDA approved
EMA approved
gptkbp:safety_features dispose of needles properly
do not share pens
monitor for hypoglycemia
gptkbp:scholarships available through manufacturer
gptkbp:side_effect weight gain
injection site reactions
hypoglycemia
gptkbp:storage refrigerated